FFR narrows cost gap by limiting repeat revascularization, data show

08/26/2013 | TCTMD.com

Although PCI initially carries higher costs than medical therapy alone for patients with abnormal fractional flow reserve, the difference narrows considerably when first-year follow-up costs are considered, according to FAME 2 data. The study of more than 1,200 patients with stable coronary artery disease and angiographically significant stenoses found those treated with PCI were less likely to need repeat revascularization. Experts said assessing FFR allows clinicians to zero in on functionally significant lesions, and appropriate use criteria should be updated accordingly.

View Full Article in:

TCTMD.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ